Pharming Group (NASDAQ:PHAR – Free Report) – Equities research analysts at HC Wainwright reduced their FY2025 earnings estimates for shares of Pharming Group in a research report issued on Tuesday, October 15th. HC Wainwright analyst J. Pantginis now forecasts that the company will earn $0.60 per share for the year, down from their prior forecast of $0.65. HC Wainwright currently has a “Buy” rating and a $37.00 price objective on the stock. The consensus estimate for Pharming Group’s current full-year earnings is ($0.15) per share.
Pharming Group Stock Performance
NASDAQ PHAR opened at $8.61 on Wednesday. The firm’s fifty day moving average price is $7.92 and its two-hundred day moving average price is $8.64. The stock has a market cap of $579.83 million, a PE ratio of -53.81 and a beta of 0.15. The company has a debt-to-equity ratio of 0.40, a quick ratio of 2.65 and a current ratio of 3.39. Pharming Group has a fifty-two week low of $6.65 and a fifty-two week high of $13.20.
Institutional Investors Weigh In On Pharming Group
An institutional investor recently raised its position in Pharming Group stock. Silverberg Bernstein Capital Management LLC lifted its position in shares of Pharming Group (NASDAQ:PHAR – Free Report) by 32.3% during the 2nd quarter, according to the company in its most recent Form 13F filing with the Securities and Exchange Commission. The fund owned 23,435 shares of the company’s stock after purchasing an additional 5,725 shares during the period. Silverberg Bernstein Capital Management LLC’s holdings in Pharming Group were worth $196,000 as of its most recent filing with the Securities and Exchange Commission. 0.03% of the stock is owned by hedge funds and other institutional investors.
About Pharming Group
Pharming Group N.V., a biopharmaceutical company, develops and commercializes protein replacement therapies and precision medicines for the treatment of rare diseases in the United States, Europe, and internationally. The company offers RUCONEST, a recombinant C1 esterase inhibitor for the treatment of acute attacks in adult and adolescent patients with acute hereditary angioedema (HAE); and Joenja (leniolisib), an oral small molecule PI3K? inhibitor for the treatment of activated phosphoinositide 3-kinase delta syndrome.
Read More
- Five stocks we like better than Pharming Group
- How to Start Investing in Real Estate
- Taiwan Semiconductor Soars on Earnings With More Room to Run
- Want to Profit on the Downtrend? Downtrends, Explained.
- Is Lucid Group Nearing the Bottom? What Investors Should Know
- How to Choose Top Rated Stocks
- 90% Gain Possible? Analysts Are Bullish on Joby Aviation
Receive News & Ratings for Pharming Group Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Pharming Group and related companies with MarketBeat.com's FREE daily email newsletter.